BRAF and metastatic neoplasm: In this subgroup, BRAF V600E/K mutation was comparable in cMKP and MUP patients (46.6% vs. 51.0%, P = 0.114), whereas patients with MUP more frequently presented with advanced and metastatic disease at primary diagnosis with worse ECOG performance status, higher LDH, and CNS metastases (Table 1).